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Abstract: Cardiovascular disease is the leading cause of death in the US. For patients with 
ST-elevation myocardial infarction (STEMI), urgent reperfusion of the culprit arterial   occlusion, 
often achieved via primary percutaneous coronary intervention (PCI), reduces post-MI 
mortality and other major adverse cardiovascular events (MACE). Adjunctive antithrombotic 
and antiplatelet therapies are used during PCI to reduce MACE rates. Currently, a variety of 
antithrombotic options are available for peri-procedural use. The most commonly used agents 
include unfractionated heparin or low molecular weight heparin ± glycoprotein IIb/IIIa inhibitors 
(GPI). These agents reduce the rates of peri-procedural ischemic and thrombotic events, though 
these benefits come at the cost of an increase in bleeding complications. Bivalirudin is a direct 
thrombin inhibitor with a short half-life and linear pharmacokinetics, which results in predictable 
serum concentrations and anticoagulant effect. Bivalirudin has emerged as an efficacious and 
safe alternative to heparin plus GP IIb/IIIa inhibitors in both stable coronary artery disease and 
acute coronary syndrome patients. In the HORIZONS-AMI trial, monotherapy with bivalirudin 
was compared with the combination of heparin and a GPI in a large population of patients with 
STEMI who underwent primary PCI. Bivalirudin treatment was associated with improved 
event-free survival at 30 days and reduced rates of major bleeding. Based on the results of the 
trial, the American College of Cardiology/American Heart Association and European Society 
of Cardiology guidelines have incorporated recommendations for bivalirudin use in the setting 
of STEMI. Recently, 3-year follow-up data from the HORIZONS-AMI cohort were published, 
demonstrating sustained benefits in patients treated with bivalirudin, including reduced rates 
of mortality, cardiovascular mortality, reinfarction, and major bleeding events. These results 
further support the use of bivalirudin in the setting of primary PCI for STEMI given that its 
benefits are maintained through long-term follow-up.
Keywords: bivalirudin, antithrombotic, ST-elevation myocardial infarction, acute coronary 
syndrome, PCI
Introduction
Cardiovascular disease is the leading cause of death in the US.1 Acute coronary syn-
dromes (ACS) are responsible for more than 1.3 million hospitalizations in the US 
annually.1 Registry data indicate that nearly 30% of these cases are due to ST-elevation 
myocardial infarctions (STEMI).2 In patients with STEMI, timely reperfusion is the 
primary goal, and this is often achieved through primary percutaneous coronary inter-
vention (PCI).3 Urgent revascularization significantly reduces the rate of cardiovascular 
mortality as well as other major adverse cardiovascular events (MACE) after MI.4,5
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In the setting of ACS, the prothrombotic clotting   cascade 
is activated, leading to the conversion of prothrombin 
to thrombin, which then converts fibrinogen to a fibrin 
  monomer.6 This fibrin production then results in platelet 
activation via prostaglandin and adenosine disphosphate-
independent mechanisms.7 Antithrombotic agents, therefore, 
are used in conjunction with revascularization to reduce 
post-MI ischemic events and to minimize thrombotic 
events peri-procedurally.8 The use of antithrombotic agents 
to this end is frequently associated with increased rates of 
bleeding complications and transfusions. Bleeding events 
and transfusions have been shown to be independent pre-
dictors of mortality in patients with ACS and in patients 
  undergoing PCI.9–11 The mechanisms by which post-PCI 
bleeding increases short- and long-term mortality are not 
well understood, but may include fatal or hemodynamically 
significant hemorrhage, temporary or permanent discontinu-
ation of cardiovascular medications in the setting of an acute 
bleed, and the prothrombotic effects of blood transfusions.12,13 
The ideal antithrombotic agent would therefore be effective 
in reducing the rates of major cardiovascular events while 
minimizing bleeding complications.
Unfractionated heparin (UFH) is the most commonly 
used antithrombotic agent in the setting of ACS.14 Heparin 
binds to and catalyzes the activity of the antithrombin, 
resulting in indirect inhibition of thrombin (Table 1).6 
Heparin is associated with high rates of bleeding after 
primary PCI, and this may be related to its inability to 
bind to clot-bound thrombin, its indirect mechanism of 
thrombin inhibition via anti-thrombin III activation, non-
specific protein binding, and non-linear pharmacokinetics.15 
Glycoprotein IIb/IIIa inhibitors (GPIs) bind to and inhibit 
the platelet IIb/IIIa receptor and are used as an adjunc-
tive therapy to heparin in primary PCI. The use of GPIs 
has been associated with reduced rates of subacute stent 
thrombosis, recurrent ischemic events, as well as with 
improved survival.16–20 However, GPIs are also associated 
with increased rates of hemorrhagic complications and 
significant thrombocytopenia.18,21,22
Bivalirudin is a direct thrombin inhibitor that has a high 
affinity and specificity for binding to the active site of throm-
bin (Table 1). Its carboxy-terminal segment competes with 
fibrinogen for access to a binding site on thrombin, and its 
amino-terminal segment attaches to the active catalytic site of 
thrombin, which is responsible for the conversion of fibrino-
gen to fibrin and the activation of clotting factors and plate-
lets. Bivalirudin is active against both unbound and bound 
thrombin. Unlike heparin, bivalirudin is not inactivated by 
platelet factor 4, does not require any cofactors for its activity, 
and does not bind to proteins or cellular matrices other than 
thrombin. The pharmacokinetics of bivalirudin are linear. 
Peak plasma concentrations with bolus dosing are achieved 
within minutes and steady-state concentrations are directly 
related to its dose. These properties of bivalirudin result in a 
more predictable anticoagulant effect as evidenced by linear 
increases in the prothrombin time, activated partial throm-
boplastin time, and activated clotting time with increasing 
intravenous bivalirudin doses. Some bivalirudin elimination 
occurs via proteolytic cleavage, but it is   primarily renally 
cleared, and dose adjustments are necessary for patients with 
renal dysfunction. Bivalirudin’s half-life is 20–25 minutes in 
patients with normal renal function. The half-life is nearly 
1 hour in patients with a CrCl between 10 and 30 mL/minute, 
and in hemodialysis patients, the half-life of bivalirudin 
is 3.5 hours.6
In a number of randomized trials of patients with stable 
CAD, unstable angina or non-ST segment elevation MI 
(NSTEMI), bivalirudin, compared with the combination of 
heparin and a GPI has been demonstrated to have similar effi-
cacy and an improved bleeding profile.23–25 The REPLACE-2 
trial, which randomized 6010 patients undergoing elective 
or urgent PCI to bivalirudin with provisional use of a GPI 
versus heparin plus a GPI, found that bivalirudin treatment 
was non-inferior to heparin plus a GPI in terms of the pri-
mary composite endpoint of the 30-day incidence of death, 
MI, urgent revascularization, and in-hospital bleeding.24 The 
ACUITY trial randomized 13,819 patients with unstable 
angina and NSTEMI to UFH or enoxaparin plus a GPI, 
Table 1 Differences in mechanisms of action between unfractionated heparin and bivalirudin
Unfractionated heparin Bivalirudin
Structure Conglomerate of heparin saccharide chains of various  
lengths with a large average molecular weight
Semi-synthetic, 20 amino acid polypeptide   
derived from hirudin
Binds Anti-thrombin III (AT III) Thrombin
Mechanism of action Indirect thrombin inhibition via binding of AT III Direct thrombin inhibition
Activity against thrombin Inhibits only thrombin that is not bound to fibrin Inhibits bound and unbound thrombin
Inactivated by Platelet factor 4 Cleavage by thrombin
Pharmacokinetics Non-linear Linear
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bivalirudin plus a GPI, or bivalirudin alone and demonstrated 
that bivalirudin monotherapy, compared with heparin plus 
a GPI, was non-inferior in terms of the 30-day composite 
ischemia endpoint of death, MI, and urgent revasculariza-
tion, while also significantly reducing the rates of major 
bleeding.25 These studies demonstrated the efficacy and safety 
of bivalirudin in low to intermediate risk ACS patients and 
set the stage for the evaluation of bivalirudin in high-risk 
STEMI patients.
The HORIZONS-AMI trial
The HORIZONS-AMI trial was an international, multicenter, 
prospective, open-label, randomized study designed to 
examine the safety and efficacy of bivalirudin monotherapy 
compared with UFH plus routine GPIs, and the paclitaxel-
eluting TAXUS stent compared with a bare metal EXPRESS 
2 stent in patients with STEMI undergoing primary PCI.26,27 
The two primary 30-day endpoints were major bleeding not 
related to coronary artery bypass grafting (CABG) and net 
adverse clinical events (NACE) defined as the composite of 
major bleeding and MACE, which included death, reinfarc-
tion, target vessel revascularization (TVR) for ischemia, 
and stroke.26 Major bleeding was defined as the occurrence 
of either intracranial bleeding, intraocular bleeding, retro-
peritoneal bleeding, access site hemorrhage requiring either 
surgery, radiologic, or interventional procedure, hematoma 
at the puncture site of at least 5 cm in diameter, a drop in 
hemoglobin concentration of at least 4 g/dL without an overt 
source of bleeding, a drop in hemoglobin concentration of at 
least 3 g/dL with an overt source of bleeding, re-operation for 
bleeding, or the use of any blood product transfusion.27
Patients included were at least 18 years of age present-
ing within 12 hours of the onset of chest pain with a STEMI 
defined as ST-segment elevation of 1 mm of more in two or 
more contiguous leads, a new left bundle-branch block, or 
a true posterior MI with ST-segment depression of at least 
1 mm. Patients who had any history that might predispose 
to or predict major bleeding were excluded. Specifically, 
major exclusion criteria included contraindications to study 
medications, prior administration of thrombolytic agents, 
bivalirudin, GPIs, low-molecular-weight heparin, or fonda-
parinux for the current admission, current use of warfarin, 
gastrointestinal or genitourinary bleeding within the   previous 
2 months, major surgery within the preceding 6 weeks, plans 
for an elective surgery that would require interruption of 
thienopyridine treatment within 6 months of enrollment, 
a platelet count less than 100,000 cells per cubic mm, 
hemoglobin less than 10 g/dL, history of bleeding diathesis, 
coagulopathy, heparin-induced thrombocytopenia, refusal 
of blood product transfusions, intracerebral mass, aneurysm, 
arteriovenous malformation, hemorrhagic stroke, stroke or 
transient ischemic attack within the previous 6 months, any 
permanent neurologic deficit, coronary stent implantation 
within the previous 30 days, and non-cardiac conditions that 
could limit life expectancy to less than 1 year or that might 
interfere with compliance with the protocol.26
Between March 2005 and May 2007, 3602 patients with 
STEMIs were enrolled at 123 medical centers in 11   countries.26 
Patients were randomized in a 1:1 fashion prior to primary 
angioplasty to UFH with a GPI versus bivalirudin with pro-
visional use of GPIs (Figure 1).   Randomization was achieved 
with an interactive voice response system that incorporated 
multiple clinical parameters into stratification including 
whether or not the patient received any non-  protocol heparin, 
whether the patient was loaded with 300 mg of clopidogrel, 
600 mg of clopidogrel, or 500 mg of ticlopidine, whether 
the patient received abciximab or eptifibatide as the GPI in 
the control arm, and whether the site was US or non-US.27 
Emergency coronary angiography was performed after 
randomization. Subsequently, the treating physician would 
decide on further management with PCI, CABG, or medical 
management. Details of the second randomization compar-
ing paclitaxel-eluting stents versus bare-metal stents will not 
be described here other than to state that after patency was 
established in the infarct-related vessel, eligible patients were 
thessn randomly assigned in a 3:1 ratio to either paclitaxel-
eluting stents or bare-metal stents.26
Bivalirudin was administered as an intravenous bolus 
of 0.75 mg/kg, followed by an infusion of 1.75 mg/kg/hour. 
Bivalirudin was to be started before PCI, though the exact 
timing of bivalirudin initiation prior to PCI was not specified. 
When UFH was used, it was administered as an intravenous 
bolus of 60 IU per kg of body weight, and subsequent boluses 
were given to achieve a target activated clotting time of 200 
to 250 seconds. Both of these antithrombin agents were to be 
discontinued at the completion of angiography or PCI, but they 
could be continued at low doses if they were clinically   indicated. 
A GPI was administered before PCI as a bolus followed by 
a continuous infusion in all patients in the control group, but 
was to be administered in the   bivalirudin group only in patients 
with no reflow or with large thrombus burden during PCI. The 
choice of GPI was left to the discretion of the operator. GPIs 
were continued for 12 to 18 hours post-PCI.27
All patients received either 324 mg of chewed, non-
enteric coated aspirin or 500 mg IV aspirin followed by 
300 to 325 mg orally daily while in the hospital and then 
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75 mg to 81 mg daily upon discharge. Clopidogrel was 
loaded at either 300 mg or 600 mg per investigator discretion 
and was then followed by 75 mg daily for at least 6 months. 
  Alternatively, if clopidogrel was either unavailable or there 
was a documented hypersensitivity to the medication, 
  ticlopidine was used. If neither of these thienopyridines could 
be tolerated, then cilostazol at a dose of 100 mg twice daily 
was to be administered for 6 months.27
The baseline features between the two anticoagulation 
groups were well matched. The median age was 60.2 years, 
and 76.6% of the patients were men. In terms of baseline car-
diovascular risk factors, 15% had diabetes, and ∼30% of those 
patients required insulin. Over 50% had hypertension, .40% 
had hyperlipidemia, and nearly half the patients were current 
smokers. Renal insufficiency was evident in 15% of patients. 
The median ejection fraction was 50% in both groups. Over 
10% had   previously suffered MIs, and a similar percentage 
had undergone previous PCI, while 3% of patients had 
  previously undergone CABG. Twenty-seven percent of 
patients were on aspirin before admission, and ∼4% were 
using   thienopyridines before admission.26
In terms of presentation, symptom onset to hospital arrival 
occurred at a median of just over 2 hours. After emergency 
angiography, the primary management strategy was primary 
PCI in 92.7% of the patients, deferred PCI in 0.2%, primary 
CABG in 1.7%, and medical management in 5.3%. Of those 
patients who underwent primary PCI, stents were implanted 
in 95.5%.26
UFH, most often as a bolus and without a continuous 
infusion, was administered before cardiac catheterization in 
3602 patients with STEMI and symptom 
onset of  ?12 hours underwent 
pharmacologic randomization 
1800 patients assigned to 
bivalirudin monotherapy with 
provisional use of a GPI
1802 patients assigned to  UFH
plus a GPI
Principal management strategy: 
Primary PCI 1678 (93.2%) 
*1182 (65.8%) received heparin 
prior to PCI 
*126 (7.5%) received bailout GPI 
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Principal management strategy: 
Primary PCI 1662 (92.2%) 
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Figure 1 The HORIZONS-AMI trial study protocol.
Abbreviations: CABG, coronary artery bypass grafting; GPI, glycoprotein IIb/IIIa inhibitors; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial 
infarction; UFH, unfractionated heparin.
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approximately two-thirds of the patients who were assigned 
to treatment with bivalirudin. In addition, 2.6% of patients 
in the bivalirudin arm received heparin during the procedure, 
and 7.5% of patients in this arm received bailout GPIs during 
primary PCI. The most common reasons for GPI use in this 
group were sustained absence of reflow after PCI or giant 
thrombus after PCI. Abciximab was used most commonly, 
followed by eptifibatide and then tirofiban. Only 0.2% of 
patients in the heparin plus GPI group received bivalirudin 
during the PCI.
In both groups, .99% of patients received aspirin during 
the hospitalization, and .97% of patients in both groups 
were discharged on aspirin. A 600 mg loading dose of 
clopidogrel was used almost twice as frequently as a 300 mg 
dose, and ∼93% of patients in both groups were discharged 
on thienopyridines. Other cardiovascular medication use at 
discharge was similar in both arms, including beta-blockers, 
angiotensin-converting enzyme inhibitors, angiotensin recep-
tor blockers, and statins.
With regard to the primary 30-day endpoints for the entire 
study population, bivalirudin monotherapy, compared with 
heparin plus a GPI, significantly reduced the rate of NACE 
(9.2% vs 12.1%, RR: 0.76, 95% CI: 0.63–0.92; P = 0.005), 
due, in large part, to a lower rate of major non-CABG-related 
bleeding (4.9% vs 8.3%, RR: 0.60, 95% CI: 0.46–0.77; 
P , 0.001), with similar rates of major adverse cardiovas-
cular events (5.4% vs 5.5%, RR: 0.99, 95% CI: 0.76–1.30; 
P = 0.950) (Table 2). The rates of major bleeding, including 
CABG-related events were also lower in the bivalirudin 
group (6.8% vs 10.8%, P , 0.001), as were the rates of 
blood transfusions (2.1% vs 3.5%, P , 0.001), thrombocy-
topenia, and hemorrhagic complications as defined by the 
Thrombosis in Myocardial Infarction (TIMI) and Global Use 
of Strategies to Open Occluded Coronary Arteries (GUSTO) 
scales. Importantly, among patients in the heparin plus GPI 
arm, the peak ACT was not significantly different in those 
patients who suffered major bleeding and those who did not. 
Neither preprocedural UFH use nor clopidogrel loading dose 
demonstrated a significant interaction with regard to either 
major adverse cardiovascular events or major bleeding.26 
Importantly, treatment with bivalirudin significantly reduced 
30-day rates of cardiovascular   mortality (1.8% vs 2.9%, RR: 
0.62, 95% CI: 0.40–0.95; P = 0.030) and all-cause mortality 
(2.1% vs 3.1%, RR: 0.66, 95% CI: 0.44–1.00; P = 0.047).
For the subgroup of patients in whom PCI was performed, 
which accounted for 93% of study patients,   treatment with 
bivalirudin as compared with heparin plus a GPI resulted 
in lower rates of major bleeding (5.1% vs 8.5%, RR: 0.59, 
95% CI: 0.46–0.77; P , 0.001), net adverse clinical events 
(9.2% vs 12.2%, RR: 0.75, 95% CI: 0.62–0.92; P = 0.005), 
and 30-day cardiovascular mortality (1.8% vs 2.8%, RR: 
0.63, 95% CI: 0.40–0.99; P = 0.045). In this PCI sub-
group, there was no difference in the two arms in terms of 
all-cause mortality at 30 days (0.2% vs 0.1%, P = 1.000). 
  Additionally, rates of reinfarction, TVR, and stroke were 
not significantly different in the two arms, whether or not 
PCI was performed.26
The lower rates of bleeding events in the bivalirudin arm 
account for the significant difference in NACE at 30 days. The 
reduction in bleeding rates was accompanied by significant 
reductions in both all-cause and cardiac mortality, although 
the composite of MACE, which included death, reinfarc-
tion, ischemia-driven TVR, and stroke, was not significantly 
different. The precise mechanism by which reduction in 
bleeding events is associated with lower mortality is not 
clear. Postulated mechanisms include reduction in fatal or 
hemodynamically significant hemorrhage, temporary or 
permanent discontinuation of cardiovascular medications in 
the setting of an acute bleed, and the prothrombotic effects 
of blood transfusions.12,13
One area of concern in the bivalirudin-treated patients 
was a higher rate of acute stent thrombosis occurring within 
24 hours (1.3% vs 0.3%, P , 0.001). This may be related 
to lower loading dose of clopidogrel (300 mg vs 600 mg) 
and not receiving UFH bolus before randomization in those 
patients. However, the overall rate of stent thrombosis at 
30 days was not significantly different in the two arms (2.5% 
vs 1.9%, P = 0.300). Furthermore, the 30-day rates of rein-
farction were similar in both arms.26
The HORIZONS-AMI trial demonstrated the superior 
safety and efficacy profile of bivalirudin monotherapy 
compared with heparin plus GPI therapy in patients with 
STEMI undergoing primary PCI. However, a number of 
limitations should be acknowledged, including the open-
label design, slight imbalances in baseline patient charac-
teristics including outpatient use of thienopyridines, the 
lack of reporting or standardization of timing of bivalirudin 
initiation prior to PCI, high rate of use of heparin in the 
bivalirudin group,   limited use of radial access which is 
known to be associated with lower rates of bleeding com-
plications, higher rate of acute stent thrombosis, lack of 
adjustment of probability values for secondary endpoints 
for multiple analyses and, perhaps most importantly, rela-
tively short-term follow-up.8,28–30
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The HORIZONS-AMI trial: 
subgroup analyses and follow-up
Following  the  publication  of  HORIZONS-AMI, 
a number of studies examining high-risk subgroups were 
published.31–33 One-year follow-up data for the 16.5% of 
patients in   HORIZONS-AMI with diabetes demonstrated 
that bivalirudin monotherapy reduced 1-year rates of car-
diovascular mortality, driven largely by reduced mortality 
in insulin-treated diabetics, though there were no significant 
differences with respect to all-cause mortality, major bleed-
ing, MACE, NACE, or stent thrombosis.31
Another 1-year follow-up study examined clinical 
outcomes in patients stratified by the CADILLAC risk 
score, a validated prognostic score for patients undergoing 
primary PCI. Patients were classified as low-, medium-, 
and high-risk based on these scores, and the CADILLAC 
score accurately identified high-risk patients based on 
receiver operator characteristic curves. In the highest 
risk group, bivalirudin monotherapy was associated with 
significantly lower rates of all-cause mortality (8.4% vs 
15.9%, RR: 0.53, 95% CI: 0.32–0.89; P , 0.010). Biva-
lirudin therapy reduced major bleeding rates in all three 
risk groups, although this reduction was only statistically 
significant in the lowest-risk patient group. One major 
limitation of this substudy was the lack of availability of 
data allowing for CADILLAC score calculation in ∼30% 
of the HORIZONS-AMI patients.32
Three year follow-up data on the chronic kidney disease 
(CKD) subgroup, which was defined as a precontrast CrCl 
of ,60 mL/minute, reaffirmed CKD as an independent 
predictor of poor cardiovascular outcomes. In this subgroup 
of patients, bivalirudin monotherapy did not result in lower 
rates of ischemic or bleeding events.33 
Importantly, all of these results should be considered 
hypothesis-generating only, as the HORIZONS-AMI trial 
was not powered for testing of superiority or non-inferiority 
of bivalirudin therapy in these subgroups.31–33
The HORIZONS-AMI trial:  
3-year follow-up
Clinical follow-up for the original HORIZONS-AMI cohort 
was planned for 30 days, 6 months, 1 year, 2 years, and 
3 years. Due to insufficient funding, planned follow-up to 
5 years was not possible, so in June 2011, Lancet published 
the final 3-year follow-up data for the HORIZONS-AMI 
cohort. Pre-specified endpoints included major bleeding 
not related to CABG, composite MACE, which included 
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death, reinfarction, ischemia-driven TVR, and stroke, as 
well as each of these individual components, and NACE, 
which was the composite of MACE and non-CABG related 
major bleeding.30
During the follow-up period, aspirin was taken by more 
than 90% of patients in both treatment arms, whereas 
thienopyridine use dropped from 93% at the discharge and 
30-day time points to 88% at 6 months. By 1 year, only 
two-thirds of patients were taking thienopyridines, and by 
3 years, thienopyridine use dropped to just one-quarter 
of patients.30
At 3 years, bivalirudin monotherapy, compared 
with heparin plus a GPI, significantly reduced rates of 
non-CABG related major bleeding (6.9% vs 10.5%, 
P = 0.0001), as well as a number of other bleeding safety 
parameters including major bleeding including CABG-
related bleeding, blood transfusion, TIMI major and minor 
bleeding, and any GUSTO bleeding (Table 2). Kaplan–
Meier analyses confirmed that after the initial benefit in 
major bleeding reduction with bivalirudin at 30 days, 
major bleeding events occurred at similar rates in both 
treatment groups.30
There were no significant changes in the rates of com-
posite MACE (21.9% vs 21.8%, P = 0.95) or NACE (25.5% 
vs 27.6%, P = 0.090). Importantly, bivalirudin treatment 
significantly reduced rates of cardiovascular mortality 
(2.9% vs 5.1%, P = 0.001), all-cause mortality (5.9% vs 
7.7%, P = 0.030), and rates of reinfarction (6.2% vs 8.2%, 
P = 0.040). The mortality, cardiac mortality, and reinfarc-
tion benefits in the bivalirudin arm increased over time. 
This reduction in all-cause mortality equates to a number 
needed to treat of 54; therefore, 18 lives would be saved 
per 1000 patients treated with bivalirudin compared with 
heparin plus a GPI.30
Bivalirudin monotherapy was associated with a trend 
towards increased rates of ischemia-driven TVR (14.2% vs 
12.1%, P = 0.06) and ischemia-driven target lesion revascu-
larization (11.3% vs 9.7%, P = 0.010), though for the 1203 
patients for whom follow-up angiographic data were avail-
able, restenosis rates were similar in both groups (12.8% vs 
12.9%, P = 0.980).30
Though there were concerns over increased rates of acute 
stent thrombosis in the bivalirudin arm from the original 
30-day data, final 3-year follow-up data demonstrated no 
statistically significant difference with regard to definite 
stent thrombosis (4.2% vs 4.1%, P = 0.870), probable stent 
thrombosis (0.3% vs 1.0%, P = 0.020), or their composite 
(4.5% vs 5.1%, P = 0.490).30
In summary, after 3 years of follow-up, bivalirudin 
montherapy as compared with heparin plus a GPI in patients 
with STEMI, most of whom underwent primary PCI, dem-
onstrated sustained benefits with significant reductions in 
all-cause mortality, cardiovascular mortality, major bleeding, 
and reinfarction, while the rates of MACE, stroke, TVR, and 
stent thrombosis were not significantly different.30
Future directions
Since the publication of the HORIZONS-AMI trial, registry 
data have indicated an increase in the use of bivalirudin in 
the setting of AMI, though heparin still remains the most 
commonly used anti-thrombotic agent.14
Based on the results of the original HORIZONS-AMI 
trial, both the European Society of Cardiology guidelines 
on acute myocardial infarction and the American College 
of   Cardiology/American Heart Association (ACC/AHA) 
STEMI guidelines incorporated stronger recommendations 
for use of bivalirudin in primary PCI.3,34 The most recent 
guidelines from the European Society of Cardiology pub-
lished in 2008 provide a Class IIa recommendation (Level of 
Evidence: B) for the use of bivalirudin as an anti-thrombotic 
therapy for primary PCI.34
Compared with the previous ACC/AHA STEMI 
guidelines from 2007, the 2009 guidelines incorporated 
bivalirudin as an acceptable anticoagulant for primary PCI 
based on the data from HORIZONS-AMI.3,35 They make 
a Class I recommendation (Level of Evidence: B) for the 
use of bivalirudin as a supportive measure for primary 
PCI with or without prior treatment with UFH. Addition-
ally, a Class IIa recommendation (Level of Evidence: B) 
states that in STEMI patients undergoing PCI who are at 
high risk of bleeding, anticoagulation with bivalirudin 
is reasonable.3
With the most recent long-term HORIZONS-AMI follow-
up data demonstrating the sustained benefits of bivalirudin 
compared with heparin plus a GPI in terms of bleeding, 
mortality and reinfarction with no loss of efficacy in ischemic 
outcomes, future STEMI guidelines will likely continue to 
support the use of bivalirudin in these high-risk patients 
undergoing primary PCI.
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